Information about the medical care and treatment of infants, children and adolescents living with HIV. Paediatric HIV treatment guidelines are different to those for adults.

HIV treatment for children and young people: latest news

HIV treatment for children and young people resources

  • HIV treatment

    HIV treatment is very effective in children with HIV, making it a long-term, manageable condition. Babies, children and adolescents – like everyone else living with HIV – are...

    From: Booklets

    Information level Level 2
  • HIV & children

    This booklet provides information about treatment and care for children living with HIV. ...

    From: Booklets

    Information level Level 2

HIV treatment for children and young people features

HIV treatment for children and young people news from aidsmap

More news

HIV treatment for children and young people news selected from other sources

  • Children, HIV and AIDS: The world today and in 2030

    The world pledged to end AIDS by 2030. While we have seen remarkable progress in the past decade among children aged 0-9 years, adolescents have been left behind in HIV prevention efforts. A staggering 360,000 adolescents are projected to die of AIDS-related diseases between 2018 and 2030 without additional investment in HIV prevention, testing and treatment programs.

    30 November 2018 | UNICEF
  • Pharmaceutical corporations are failing children with HIV

    One year ago, pharmaceutical corporations committed to improving access to paediatric versions of HIV drugs for children, but very little progress has been made. MSF urges pharmaceutical corporations including Viiv and Merck to immediately register paediatric ARVs and improve access for kids.

    30 November 2018 | Médecins Sans Frontières (MSF)
  • MSF: Pharmaceutical corporations failing children with HIV

    Developing countries are struggling to provide HIV-positive children with World Health Organization (WHO)-recommended treatments because pediatric versions of HIV medicines don’t exist, are priced out of reach, or haven’t been registered in all countries that need them, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ahead of a Vatican City meeting of HIV stakeholders on scaling up diagnosis and treatment for children.

    29 November 2018 | Doctors Without Borders
  • In Utero HIV Infection Sharply Increases Cytomegalovirus Risk for Newborns

    Nearly 1 in 4 infants who acquire HIV infection in the womb will also contract congenital cytomegalovirus (CMV), according to new research.

    09 November 2018 | MD Magazine
  • Adolescents and HIV: kindness and time key factors for treatment retention

    New research from South Africa provides insights into the factors associated with retention of adolescents in HIV care, suggesting relatively low‐cost interventions could significantly improve adherence and retention in care.

    15 October 2018 | AVERT
  • Vatican makes progress on pushing drug availability for kids with HIV

    An initiative to identify and properly treat children living with HIV has gained new momentum as international organizations and pharmaceutical companies respond to a Vatican push to look past profit to doing the right thing.

    10 August 2018 | Crux: Covering all things Catholic
  • Pfizer and GSK's HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine

    Despite ViiV pledging in November 2017 that it would expedite the availability of paediatric dolutegravir formulations where these are most critically needed, and despite repeated appeals from MSF and others, almost 18 months after paediatric formulations of dolutegravir were approved for use by the European Medicines Agency, the corporation has started the registration process in only three sub-Saharan African countries

    23 July 2018 | Médecins Sans Frontières (MSF) International
  • More than half of children living with HIV still without treatment in high burden, PEPFAR-supported southern African countries

    Data across 20 countries receiving PEPFAR support showed 56 percent of children living with HIV under the age of 15 — an estimated 750,000 children — are not receiving the life-saving treatment that also prevents transmission of the virus.

    18 May 2018 | Science Speaks
  • UK Adolescents with Perinatally-Acquired HIV Are Not at Increased Risk of Anxiety, Depression

    Adolescents and Adults Living with Perinatal HIV (AALPHI) is an ongoing study in the United Kingdom that follows a cohort of young people with perinatally-acquired HIV (PHIV) and a control group of HIV-affected youth, who have a parent, sibling, or other household member living with HIV.

    24 March 2018 | MD Magazine
  • HIV drug resistance found in more than half of young children in Africa

    Approximately 54% of young children with HIV surveyed in Africa had resistance to one or more antiretroviral drugs, according to recent data.

    24 August 2017 | Healio
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.